Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals

Sharada Saraf¹, Xianming Zhu², Ruchee Shrestha², Tania S. Bonny²,⁶, Owen R. Baker³, Evan J. Beck¹, Reinaldo E. Fernandez³, Yolanda Eby², Olivia Akinde², Jessica E. Ruff², Patrizio Caturegli², Andrew D. Redd¹,³, Evan M. Bloch², Thomas C. Quinn¹,²,³, Aaron A. R. Tobian²,³,⁴, Oliver Laeyendecker¹,³*  

¹ Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, ² Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America, ³ Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America, ⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America  

* Current address: U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America  
* olaeyen1@jhmi.edu

Abstract
The association between COVID-19 symptoms and antibody responses against SARS-CoV-2 is poorly characterized. We analyzed antibody levels in individuals with known SARS-CoV-2 infection to identify potential antibody-symptom associations. Convalescent plasma from 216 SARS-CoV-2 RNA+ individuals with symptomatology information were tested for the presence of IgG to the spike S1 subunit (Euroimmun ELISA), IgG to receptor binding domain (RBD, CoronaCHEK rapid test), and for IgG, IgA, and IgM to nucleocapsid (N, Bio-Rad ELISA). Logistic regression was used to estimate the odds of having a COVID-19 symptom from the antibody response, adjusting for sex and age. Cough strongly associated with antibodies against S1 (adjusted odds ratio [aOR] = 5.33; 95% CI from 1.51 to 18.86) and RBD (aOR = 4.36; CI 1.49, 12.78). In contrast, sore throat significantly associated with the absence of antibodies to S1 and N (aOR = 0.25; CI 0.08, 0.80 and aOR = 0.31; CI 0.11, 0.91). Similarly, lack of symptoms associated with the absence of antibodies to N and RBD (aOR = 0.16; CI 0.03, 0.97 and aOR = 0.16; CI 0.03, 1.01). Cough appeared to be correlated with a seropositive result, suggesting that SARS-CoV-2 infected individuals exhibiting lower respiratory symptoms generate a robust antibody response. Conversely, those without symptoms or limited to a sore throat while infected with SARS-CoV-2 were likely to lack a detectable antibody response. These findings strongly support the notion that severity of infection correlates with robust antibody response.

Introduction
The ongoing COVID-19 pandemic has challenged health care systems globally and necessitated rapid deployment of treatments and vaccines. SARS-CoV-2 infection, the causative agent...
of COVID-19, elicits a broad range of symptoms: fever, cough, shortness of breath, and myalgia are the most reported symptoms among critically ill patients [1]. Antibody levels serve as a potential correlate of protection against COVID-19; individuals who test positive for anti-spike and anti-nucleocapsid IgG antibodies have demonstrated a substantially reduced risk of SARS-CoV-2 reinfection [2]. Moreover, high vaccine-induced antibody responses are associated with lower risk of symptomatic COVID-19 [3].

Previous studies have observed higher prevalence of seroconversion among severely ill individuals versus those with asymptomatic or mild disease [4]. Additionally, studies have shown that males, older individuals, and those previously hospitalized with symptoms generate strong antibody responses [5]. SARS-CoV-2 antibody levels have been demonstrated to positively correlate with the severity of COVID-19; however, the immune responses of individuals experiencing milder disease remain poorly characterized [6–8]. Investigating possible correlations with symptomatology can add more nuance to characterizing population level immunity or seroprevalence in a certain population, thus informing future public health interventions [7,9]. Furthermore, these data may help inform whether previously infected individuals have a higher chance of re-infection depending on their symptom presentation during their disease course, which can better characterize the urgency of vaccination in these individuals [10,11].

We investigated whether certain symptoms are predictive of a stronger antibody response by analyzing the antibody levels of individuals with known SARS-CoV-2 infection for associations between antibody response and reported symptoms. Samples from individuals who recovered from SARS-CoV-2 infection were tested for the presence of IgG antibodies to spike (S1), IgG antibodies to the receptor binding domain (RBD), and total antibodies to nucleocapsid (N).

**Materials and methods**

**Study participants**

This study used stored samples and data from studies that were approved by The Johns Hopkins University School of Medicine Institutional Review Board. All study participants provided written informed consent and were de-identified prior to laboratory testing.

To assess the antibody levels of SARS-CoV-2 infected individuals, samples from 216 participants from the Baltimore/Washington DC area who were screened to donate COVID-19 convalescent plasma (CCP) and had accompanying symptom data from April 2020-January 2021 were evaluated [5,12,13]. All were at least 18 years old and met the eligibility criteria for blood donation. Participants were engaged in a larger clinical trial investigating the use of convalescent plasma for prevention and treatment of COVID-19; recruitment efforts included community referral, employee referral, and existing blood donation registries. These were targeted at individuals in the Baltimore/Washington DC area who had a positive test for COVID-19 and were symptom-free at the time of screening. 22.6% of participants reported being medical professionals. The exclusion criteria included receipt of any experimental COVID-19 medication or vaccine as well as antiplatelet agents, anticoagulants, isotretinoin, finasteride, dutasteride, vismodegib, teriflunomide, acitretin, etretinate, and hepatitis B immune globin.

**Ascertainment of the symptomatology**

As a part of a phone screening, participants were asked by a study team member if they were hospitalized and/or experienced any symptoms during their illness and, if so, to list their symptoms. Participant answers were then recorded by the screener according to 17 standard categories: no symptoms, fever, cough, chills, shortness of breath, diarrhea, fatigue, anosmia, dysgeusia, sore throat, headache, muscle ache, runny nose, stuffy nose, nausea, vomiting, or other.
Laboratory methods

Plasma was separated from whole blood within 12 hours of collection and stored at −80°C until further testing. Samples were analyzed using three commercially available serologic assays: Euroimmun Anti-SARS-CoV-2 ELISA (Mountain Lakes, NJ), the CoronaCHEK™ COVID-19 IgG/IgM Rapid Test Cassette (Hangzhou Biotest Biotech Co Ltd), and the Bio-Rad Platelia SARS-CoV-2 Total Antibody ELISA (Marnes-la-Coquette, France). The Euroimmun ELISA measures IgG responses to the SARS-CoV-2 S1 protein; the manufacturer reported an estimated sensitivity of 90% (95% CI 74%, 97%) and specificity of 100% (95% CI 95%, 100%) [14]. The CoronaCHEK rapid test measures IgG responses to the SARS-CoV-2 RBD, with a reported sensitivity of 97% (95% CI 83%, 99%) and specificity of 98% (95% CI 91%, 99%) [14,15]. The Bio-Rad ELISA measures total antibody response to the SARS-CoV-2 N, with a reported plasma sensitivity of 96% (95% CI 79%, 99%) and specificity of 100% (95% CI 99%, 100%) [16].

Thirty-five cytokine and chemokine analytes in plasma were assessed using a multi-array electrochemiluminescence detection technology (MesoScale Discovery, Gaithersburg, MD) as previously described [17]. Analytes with ≥80% overall detectability were evaluated for cytokine level differences between symptom groups and included Eotaxin, Eotaxin-3, IFN-γ, IL-12/IL23p40, IL-15, IL-16, IL-17A, IL-18, IL-1RA, IL-6, IL-7, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1β, TARC, TNF-α, and VEGF-A. Analytes with <80% overall detectability were evaluated for percent detectability differences between symptom groups and included IL-12p70, IL-13, IL-1β, IL-2, IL-4, G-CSF, IFN-α2a, IL-21, IL-33, IL-8(HA), MIP-1α, GM-CSF, IL-1α, IL-5, and TNF-β. All assays were performed according to the manufacturer’s protocols.

Statistical analysis

Binomial logistic regressions were performed to calculate odds ratios [OR] for associations between serological results and reported symptoms. Adjusted odds ratios [aOR] were calculated for all symptoms. Based on previous studies linking sex and age to antibody reactivity, these were considered to be confounding variables and therefore included in adjusted models [5]. Adjusted odds ratios with a p<0.05 were considered significant. All analysis were performed in STATA v.14.2 (College Station, TX).

Results

Participants were a median age of 49 years (IQR 37–58) at the time of sample collection. This subject pool was 81.9% White, 9.7% Black, 4.2% Asian, and 4.2% mixed/other/unknown (Table 1). A median of 49 days (IQR 40–64) had elapsed since participants had a confirmed SARS-CoV-2 diagnosis via detectable RNA.

Of the 17 different categories, the most frequently reported were fatigue (53%), fever (50%), and cough (50%) (Fig 1). Headache (44%), muscle ache (43%), loss of smell (38%), altered taste (33%), short breath (26%), stuffy nose (25%), and sore throat (20%) were also commonly reported. Chills (16%), diarrhea (15%), nausea (9%), runny nose (8%), no symptoms (5%), and vomiting (3%) were the least recorded categories. Hospitalization occurred in 7% of all participants. Individuals reporting fatigue also commonly reported headache (29%), fever (26%), cough (26%), and muscle ache (26%).

For each of the three serologic assays, >83% of all samples had a positive result. All individuals who were hospitalized had reactive plasma to the Euroimmun ELISA, CoronaCHECK (IgG) rapid test, and Bio-Rad ELISA. For individuals reporting shortness of breath reactivity on Euroimmun, CoronaCHECK IgG, and Bio-Rad assays were positive on 93%, 91%, and 86% respectively (Fig 2). Other symptoms had similar consistency in reactivity, with fever and cough specifically demonstrating a similar range of percent reactivity (88–94%) across the
three assays. Similarly, lack of reactivity to these two assays appeared to be consistent, with the exception of vomiting. Lack of symptoms (40–60%) and sore throat (73–75%) demonstrated relative stability across all three assays.

Signal to cut-off ratios (S/C) were generated for the Euroimmun and BioRad ELISAs. These results were stratified by five symptom categories: cough, sore throat, no symptoms, and other symptoms (Fig 3). For the Bio-Rad assay, individuals reporting cough or other symptoms had the highest mean S/C ratio. Sore throat and no symptoms had the lowest mean S/C ratio. Similarly, the highest S/C ratios on the Euroimmun assay were generated by samples from individuals reporting cough, other symptoms, sore throat, and no symptoms.

Individuals reporting cough had the strongest association with a positive antibody response to S1 (aOR = 5.33; 95% CI 1.51, 18.86) and RBD (aOR = 4.36; CI 1.49, 12.78) though not to N
In contrast, sore throat was significantly associated with a lack of detectable antibody response to S1 and N (aOR = 0.25; CI 0.08, 0.80 and aOR = 0.31; 0.11, 0.91), respectively. Reporting a lack of symptoms was associated with a lack of antibody response to N (aOR = 0.16; CI 0.03, 0.97) and to RBD, though this association did not reach a statistical significance of <0.05 (aOR = 0.16; CI 0.03, 1.01). Individuals reporting diarrhea demonstrated decreased reactivity to N (aOR = 0.17; CI 0.05, 0.62). Notably, aORs and confidence intervals did not significantly attenuate after adjustment across assays for cough, sore throat, or no symptoms.

To further investigate the seronegativity of individuals reporting sore throat, individuals were grouped into three categories: whether they reported no symptoms, reported symptoms other than sore throat, or reported sore throat. Individuals who reported a sore throat and cough as co-symptoms were placed in the second category. Among the analytes with ≥80% overall detectability, the median cytokine levels were not significantly higher among convalescent individuals who were symptomatic, asymptomatic, or reporting sore throat (Fig 4). Among the analytes with <80% overall detectability, the percent detectability analytes in individuals reporting sore throat (no cough) versus other symptoms were not significantly different (Fig 5).

**Discussion**

This study demonstrates associations between symptom presentation and antibody assay reactivity. Assay reactivity appears to be consistent across symptoms, suggesting that antibodies produced by convalescent individuals share a similar responsiveness to different parts of the virus regardless of symptom presentation. In addition to hospitalization and male sex, reporting cough appeared to be predictive of a seropositive result, suggesting that these individuals may be more likely to generate a robust antibody response. Conversely, sore throat and no symptoms were associated with a seronegative result.
Fig 3. Antibody reactivity to nucleocapsid protein as measured by Bio-Rad ELISA and S1 protein as measured by Euroimmun ELISA stratified by symptom category. Solid horizontal lines represent the mean S/C ratio for the indicated symptom group. Dashed horizontal line represents the positive result threshold for the indicated assay.

https://doi.org/10.1371/journal.pone.0264298.g003
Previous studies have demonstrated higher antibody titers in individuals exhibiting more symptomatic disease [4,18]. Our results are complementary to these findings, given that asymptomatic convalescent individuals were significantly associated with a seronegative result. Strikingly, our study demonstrates the single symptom of sore throat being associated with a seronegative result. This finding has not been demonstrated in prior studies investigating COVID-19 symptoms and antibody reactivity. However, the lower and upper respiratory tract has shown to differ in their mechanisms of immunity, with sore throat being a presenting symptom of an upper respiratory tract infection [19–21].

Studies regarding influenza have demonstrated robust IgG responses to be more indicative of a lower respiratory tract infection [22,23]. Moreover, others have suggested that the progress
of COVID-19 disease, when confined to the upper respiratory tract, typically appears to resolve with minimal to no symptoms [24]. This literature may serve as a potential explanation as to why convalescent individuals in this study reporting no symptoms (n = 10), sore throat and no cough (n = 24), and all other symptoms (n = 182) are shown in green, red, and blue, respectively.

https://doi.org/10.1371/journal.pone.0264298.g005

Fig 5. Detectability of cytokine and chemokine markers by response panel and symptom group. Cytokine and chemokine analytes with <80% detectability in the overall participant group are shown according to MSD panel. Individuals reporting no symptoms (n = 10), sore throat and no cough (n = 24), and all other symptoms (n = 182) are shown in green, red, and blue, respectively.

of COVID-19 disease, when confined to the upper respiratory tract, typically appears to resolve with minimal to no symptoms [24]. This literature may serve as a potential explanation as to why convalescent individuals in this study reporting no symptoms and sore throat generate fewer IgG antibodies. Alternatively, a strong innate immune response may serve to effectively combat the virus in these convalescent individuals, thus not necessitating a robust antibody response; Xu et al. measured cytokine, chemokine, and growth factor levels in COVID-19 patients with varying levels of disease severity and found that PDGF-BB, CCL5/RANTES, IL-9, TNF-β, and CCL4/MIP-1β are upregulated to higher levels in mild than severe and/or fatal COVID-19 patients [25]. However, our cytokine and chemokine data, which included TNF-β
and MIP-1β, do not demonstrate any significant differences among symptom groups and therefore do not support this rationalization. Given that a median of 30 days had passed since symptom resolution in this subject pool at the time of blood collection, it is possible that cytokine and chemokine levels may have declined to their basal levels [26].

Our study had several limitations. First, capture of clinical symptoms was based on self-reporting rather than review of the patients' medical records. Individuals reporting a certain symptom may have experienced a more severe presentation than others reporting the same symptom, which was not captured by this dataset and may have influenced antibody production. Second, samples were obtained a median of 49 days after participants had PCR positive results and 30 days post symptom resolution. Antibody levels may have declined at the time of sample collection; furthermore, samples were collected at only one timepoint and inferences about persistently high titers of antibodies based on symptom cannot be made. Moreover, current literature strongly suggests that neutralizing antibody levels are associated with disease severity; individuals with severe COVID-19 have been shown to develop higher neutralizing titers compared to patients with mild disease [27]. Neutralizing antibody assay result may have an association with symptom categories, but this was assay was not available to us and therefore not investigated by this study.

In this cohort of known SARS-CoV-2 infected individuals, we found a strong association between cough and antibody response. Conversely, a sore throat was strongly associated with a lack of antibody response to SARS-CoV-2 infection. Future studies could test for IgA levels in nasal or throat samples to evaluate whether a robust mucosal IgA response is associated with certain clinical presentations of COVID-19. Immune factors other than IgG antibodies, total antibodies, and our panel of human cytokines may also be evaluated to better characterize the immune responses generated by individuals exhibiting particular symptomatology.

Supporting information

S1 Data.
(XLSX)

Acknowledgments

The authors would like to thank the participants who donated their plasma and the study trial staff, without whom this investigation could not be conducted.

Author Contributions

Conceptualization: Aaron A. R. Tobian, Oliver Laeyendecker.

Data curation: Xianming Zhu, Ruchee Shrestha, Yolanda Eby, Olivia Akinde, Jessica E. Ruff.

Formal analysis: Sharada Saraf, Xianming Zhu, Ruchee Shrestha, Tania S. Bonny, Owen R. Baker, Evan J. Beck, Reinaldo E. Fernandez, Evan M. Bloch.

Funding acquisition: Evan M. Bloch.

Investigation: Sharada Saraf, Tania S. Bonny, Owen R. Baker, Evan J. Beck, Olivia Akinde, Jessica E. Ruff, Patrizio Caturegli, Oliver Laeyendecker.

Methodology: Xianming Zhu, Patrizio Caturegli.

Supervision: Reinaldo E. Fernandez, Yolanda Eby, Andrew D. Redd, Aaron A. R. Tobian, Oliver Laeyendecker.
Validation: Sharada Saraf.

Visualization: Andrew D. Redd, Thomas C. Quinn, Oliver Laeyendecker.

Writing – original draft: Sharada Saraf, Reinaldo E. Fernandez, Andrew D. Redd, Thomas C. Quinn, Aaron A. R. Tobian, Oliver Laeyendecker.

Writing – review & editing: Xianming Zhu, Ruchee Shrestha, Tania S. Bonny, Owen R. Baker, Evan J. Beck, Yolanda Eby, Olivia Akinde, Jessica E. Ruff, Patrizio Caturegli, Andrew D. Redd, Evan M. Bloch, Thomas C. Quinn, Aaron A. R. Tobian, Oliver Laeyendecker.

References

1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020; 8(5):475–481. https://doi.org/10.1016/S2213-2600(20)30079-5 PMID: 32105632

2. Lumley SF, O’Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in healthcare workers. New England Journal of Medicine. 2021; 384(6):533–540. https://doi.org/10.1056/NEJMoa2034545 PMID: 33588689

3. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 2021; 27:11. 2021; 27(11):2032–2040. https://doi.org/10.1038/s41591-021-01540-1 PMID: 34588689

4. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications 2021 12:1. 2021; 12(1):1–8.

5. Klein SL, Pekosz A, Park H, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020; 130(11):6141–6150. Accessed Jan 7, 2022. https://doi.org/10.1172/JCI142004 PMID: 32764200

6. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine 2020; 26:8. 2020; 26(8):1200–1204. https://doi.org/10.1038/s41591-020-0965-6 PMID: 32555424

7. Grossberg AN, Koza LA, Ledreux A, et al. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nature Communications 2021 12:1. 2021; 12(1):1–11.

8. Caturegli G, Materi J, Howard BM, Caturegli P. Clinical validity of serum antibodies to SARS-CoV-2. Ann Intern Med. 2020; 173(8):614–622. https://www.acpjournals.org/doi/10.7326/M20-2889. Accessed Jan 20, 2022. PMID: 32628534

9. Smith DR. Herd immunity. Veterinary Clinics of North America: Food Animal Practice. 2019; 35(3):593–604.

10. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by SARS-CoV-2: A comparative evolutionary study. The Lancet Microbe. 2021; 2(12):e666–e675. https://doi.org/10.1016/S2666-5247(21)00219-6 PMID: 34632431

11. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. MMWR. Morbidity and Mortality Weekly Report. 2021; 70(32):1081–1083.

12. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. Journal of Clinical Microbiology. 2020. https://journals.asm.org/doi/abs/10.1128/JCM.02257-20. Accessed Jan 11, 2022. PMID: 32908987

13. Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. The Journal of Infectious Diseases. 2020; 222(12):1974–1984. https://doi.org/10.1093/infdis/jiaa581 PMID: 32910175

14. EUROMMUN US. Anti-SARS-CoV-2 ELISA (IgG) instruction for use. https://www.fda.gov/media/137609/download. Updated 2020.

15. Healgen. COVID-19 IgG/IgM rapid test cassette (whole blood/serum/plasma) instruction for use. https://www.fda.gov/media/138438/download. Updated 2020.

16. Plateia SARS-CoV-2 total ab. https://www.fda.gov/media/137493/download. Updated 2022.

17. Bonny TS, Patel EU, Zhu X, et al. Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma. Open Forum Infectious Diseases. 2021; 8(2). https://doi.org/10.1093/ofid/ofaa574 PMID: 33538673
18. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* 2020;26(6):845–848. https://doi.org/10.1038/s41591-020-0897-1 PMID: 32350462

19. Hodge LM, Simecka JW. Role of upper and lower respiratory tract immunity in resistance to mycoplasmal respiratory disease. *The Journal of Infectious Diseases*. 2002; 186(2):290–294. https://doi.org/10.1086/341280 PMID: 12134269

20. Subbarao K, Mahanty S. Respiratory virus infections: Understanding COVID-19. *Immunity*. 2020; 52(6):905. https://doi.org/10.1016/j.immuni.2020.05.004 PMID: 32497522

21. Thomas M, Bomar PA. Upper respiratory tract infection. *Medscape*. 2021;1–18.

22. Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. *The Journal of Immunology*. 2004; 173(3):1978–1986. https://doi.org/10.4049/jimmunol.173.3.1978 PMID: 15265932

23. Ito R, Ozaki YA, Yoshikawa T, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. *Vaccine*. 2003; 21(19):2362–2371. https://www.sciencedirect.com/science/article/pii/S0264410X03000781. Accessed Jan 12, 2022. https://doi.org/10.1016/s0264-410x(03)00078-1 PMID: 12744867

24. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection. *Frontiers in Immunology*. 2020; 11:3221. https://doi.org/10.3389/fimmu.2020.611337 PMID: 33329607

25. Xu Z, Shu T, Kang L, et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. *Sig Transduct Target Ther*. 2020; 5(1):1–3. https://doi.org/10.1038/s41392-020-0211-1 PMID: 32561706

26. Whiteside TL. Cytokines and cytokine measurements in a clinical laboratory. *Clin Diagn Lab Immunol*. 1994; 1(3):257–260. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC368245/. Accessed Jan 20, 2022. https://doi.org/10.1128/cdi.1.3.257-260.1994 PMID: 7496959

27. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody responses in COVID-19: A review. *Frontiers in immunology*. 2021; 12:633184. https://doi.org/10.3389/fimmu.2021.633184 PMID: 33936045